Study #2022-0998
An open label, Phase 1/2 study of HST-1011 given as Monotherapy and in combination with an Anti-PD1 Antibody in patients with advanced solid tumors
MD Anderson Study Status
Not Accepting
Treatment Agent
HST-1011, Cemiplimab
Description
This is a Phase 1/2 study of HST-1011, a CBL-B inhibitor, being developed for the treatment of patients with advanced solid tumors, who relapsed while on or are refractory to approved anti-PD(L)1 therapies or other standard of care.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Solid Tumor, Adult, Relapsed Cancer, Refractory Cancer
Study phase:
Physician name:
Jordi Rodon Ahnert
Department:
Investigational Cancer Therapeutics
For general questions about clinical trials:
1-844-491-2084
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.